Recurrence of LV Thrombus in a Patient with Severe Ischaemic Cardiomyopathy Anticoagulated with Apixaban.

IF 0.6 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Case Reports in Cardiology Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI:10.1155/2022/8156942

Azhar Farooqui, Tin Lwin, Daniel Costa, Simon Hetherington, Raj Mattu

{"title":"Recurrence of LV Thrombus in a Patient with Severe Ischaemic Cardiomyopathy Anticoagulated with Apixaban.","authors":"Azhar Farooqui, Tin Lwin, Daniel Costa, Simon Hetherington, Raj Mattu","doi":"10.1155/2022/8156942","DOIUrl":null,"url":null,"abstract":"Background: Anticoagulation with warfarin remains the mainstay treatment for left ventricular thrombi. Although successful thrombus resolution has been reported with direct oral anticoagulants' (DOACs') recurrence/progression while resuming Apixaban therapy is yet to be reported. Case Presentation. This case report describes left ventricular thrombus progression/recurrence in a patient anticoagulated with Apixaban undergoing implantable cardioverter defibrillator to cardiac resynchronisation therapy with defibrillator upgrade procedure. He was thereafter changed to warfarin. Contrast echocardiogram at 6 months follow-up did not identify the previously demonstrated mural thrombus.Conclusion: Prospective randomised control trials should be conducted in patients with left ventricular thrombus to compare anticoagulants, assess the efficacy and safety of DOACs, and evaluate uninterrupted DOAC versus transient withdrawal for cardiac device procedures.","PeriodicalId":51760,"journal":{"name":"Case Reports in Cardiology","volume":" ","pages":"8156942"},"PeriodicalIF":0.6000,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334074/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/8156942","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Anticoagulation with warfarin remains the mainstay treatment for left ventricular thrombi. Although successful thrombus resolution has been reported with direct oral anticoagulants' (DOACs') recurrence/progression while resuming Apixaban therapy is yet to be reported. Case Presentation. This case report describes left ventricular thrombus progression/recurrence in a patient anticoagulated with Apixaban undergoing implantable cardioverter defibrillator to cardiac resynchronisation therapy with defibrillator upgrade procedure. He was thereafter changed to warfarin. Contrast echocardiogram at 6 months follow-up did not identify the previously demonstrated mural thrombus.

Conclusion: Prospective randomised control trials should be conducted in patients with left ventricular thrombus to compare anticoagulants, assess the efficacy and safety of DOACs, and evaluate uninterrupted DOAC versus transient withdrawal for cardiac device procedures.

Abstract Image

查看原文本刊更多论文

阿哌沙班抗凝治疗严重缺血性心肌病患者左室血栓复发的研究

背景:华法林抗凝仍然是左心室血栓的主要治疗方法。虽然有直接口服抗凝剂(DOACs)成功解决血栓的报道，但恢复阿哌沙班治疗时复发/进展尚未报道。案例演示。本病例报告描述了一名接受阿哌沙班抗凝治疗的患者，在接受植入式心律转复除颤器到心脏再同步治疗和除颤器升级程序后，左心室血栓进展/复发。此后他被改为华法林。6个月随访时的超声心动图造影未发现先前显示的附壁血栓。结论:应在左心室血栓患者中进行前瞻性随机对照试验，以比较抗凝剂，评估DOAC的有效性和安全性，并评估不间断DOAC与心脏装置程序的短暂停药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Case Reports in Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Case Reports in Cardiology is a peer-reviewed, Open Access journal that publishes case reports and case series related to hypertension, arrhythmia, congestive heart failure, valvular heart disease, vascular disease, congenital heart disease and cardiomyopathy.